These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1342665)

  • 1. [Genetic polymorphism and metabolism of tricyclic antidepressants].
    Samyn B
    Encephale; 1992; 18(6):661-4. PubMed ID: 1342665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F; Bertilsson L
    Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
    Jaruratanasirikul S; Cooper AD; Blaschke TF
    Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of antidepressant drugs: pharmacogenetics.
    Sjöqvist F; Bertilsson L
    Adv Biochem Psychopharmacol; 1984; 39():359-72. PubMed ID: 6380229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
    Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of dextromethorphan oxidation in South Indian subjects.
    Mamidi RN; Satyavageeswaran S; Vakkalanka SV; Chaluvadi MR; Katneni K; Brahmadevara N; Damodarram G; Subramaniam S
    Clin Pharmacol Ther; 1999 Aug; 66(2):193-200. PubMed ID: 10460073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population.
    Duché JC; Quérol-Ferrer V; Barré J; Mésangeau M; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):392-8. PubMed ID: 8225685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical importance of genetic polymorphism of drug oxidation.
    Edeki T
    Mt Sinai J Med; 1996; 63(5-6):291-300. PubMed ID: 8898530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of dextromethorphan O-demethylation in man.
    Küpfer A; Schmid B; Pfaff G
    Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism of cytochrome P-450-dependent phencyclidine hydroxylation in mice. Comparison of phencyclidine hydroxylation in humans.
    Holsztynska EJ; Weber WW; Domino EF
    Drug Metab Dispos; 1991; 19(1):48-53. PubMed ID: 1673421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
    Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
    Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Knowledge about metabolic capacity is important in drug therapy].
    Alván G; Dahl ML
    Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA; Syrek M; Ryłko Z; Wójcikowski J
    Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.
    Schmid B; Bircher J; Preisig R; Küpfer A
    Clin Pharmacol Ther; 1985 Dec; 38(6):618-24. PubMed ID: 4064464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
    Caporaso NE; Shaw GL
    Arch Intern Med; 1991 Oct; 151(10):1985-92. PubMed ID: 1681790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.